New obesity drug survodutide shows groundbreaking results in late-stage trials

A new obesity drug called survodutide is moving through late-stage testing after showing strong results in earlier trials. Developed by Boehringer Ingelheim and Zealand Pharma, the treatment has already gained fast-track status from the U.S. FDA and accelerated review in Europe. Researchers are now awaiting final data to seek approval by 2027 or 2028.

Survodutide works by activating two key hormones: GLP-1, which controls appetite and insulin, and glucagon, which helps break down fat in the liver. This dual action slows digestion, reduces hunger, and improves metabolism.

The drug first received FDA fast-track designation in 2021 for obesity-related conditions. Phase 2 trials between 2022 and 2023 delivered promising outcomes. Patients without diabetes lost up to 19% of their body weight—around 19.5 kg on average—over 46 weeks. Waist sizes shrank by up to 16 cm, while blood pressure dropped by as much as 8.6 mmHg (systolic) and 4.8 mmHg (diastolic).

For those with metabolic dysfunction-associated steatotic liver disease (MASH), survodutide showed particular benefit. In one study, 65% of participants with moderate to advanced liver scarring (F2 and F3 fibrosis) saw improvements. These results led to the launch of Phase 3 trials, including the LIVERAGE program for MASH patients, which began in 2024.

The European Medicines Agency granted the drug accelerated assessment in 2023, speeding up the review process. As of early 2026, Phase 3 data is still being analysed, with no approval yet granted. The companies aim for market authorisation between 2027 and 2028.

If approved, survodutide could offer a new option for weight management and liver disease linked to obesity. The drug's ability to target multiple metabolic pathways sets it apart from existing drugs. Final regulatory decisions will depend on the ongoing Phase 3 results.